Jonathan (“Jon”) Soll is an investment professional who currently serves as a Vice President on the investment team at New Rhein Healthcare Investors. In his role he leads evaluation of new venture investment opportunities in the biopharma and medical technology industries. In addition, he is deeply involved in the support of existing investments, including prior interim operational roles at Sayvaa Pharma and Alveus Therapeutics. Jon currently serves as the Interim Chief Executive Officer at a stealth cardiovascular-focused biotechnology company within the New Rhein portfolio. Prior to New Rhein, Jon was an analyst at Denovo Capital Group, an event-driven investment fund. At Denovo, he developed a successful investment strategy focused on special situations within the healthcare sector. Jon started his career in the data analytics group at Quicken Loans, where he worked with various areas of the business to drive data-driven decisions. Jon holds a Bachelor of Business Administration degree from the Stephen M. Ross School of Business at the University of Michigan. Further education includes completion of the American Course on Drug Development and Regulatory Sciences at the University of California, San Francisco.